Concord Dependency Seminar Summaries

Concord Seminar sessions for 2010.

2/02/2010 The Exit Strategy Part 1: Naltrexone Implants: What does the evidence tell us? Ross Colquhoun

20/04/2010 Wet Brain: Alcohol and the Brain - delerium, confabulation, amnesia, and collapse. Prof Paul Haber

8/06/2010 The Other Hepatitis"- An Update on Hepatitis B Part 2 Dr Gail Matthews

Tues 3/08/2010 - Is pathological gambling an addiction? You bet it may or may not be! Prof Alex Blaszczynski

Tues 21/09/2010 - Mentally Disordered or Mentally Ill? The NSW Mental Health Act, and how to use it in drug and alcohol settings and in community practice.
Dr Glenys Dore & Dr Lisa Juckes

30/11/2010 The Exit Strategy Part 2: Is there life after methadone? Prof Nicholas Lintzeris


Organisation:

No booking necessary. 6.30pm for introductions and refreshments, session starts 7pm. Parking available at front of Concord Hospital. Conference Room 1, opposite hospital cafeteria. For information call Dr Richard Hallinan or Dr Andrew Byrne (02) 9319 5524. GP CPD credits available.

This seminar series has been set up as a regular activity attracting 2 points/hours for RACGP QA&CPD (activity number 745701)

Objectives and prereading will be circulated prior to each seminar (some details below).

Sponsored by Reckitt Benckiser, manufacturers of buprenorphine products.


THE CONCORD DEPENDENCY SEMINARS 2010 CALENDAR AND PRE-READING:

2/02/2010 - The Exit Strategy Part 1: Naltrexone Implants: What does the evidence tell us?Ross Colquhoun & Richard Hallinan

Naltrexone implants have been used for opioid dependence in Australia since about 2001, usually following "rapid opioid detox" procedures. So far they are only used in a small number of centres. Since 2001 published literature has built up, much of it post hoc and naturalistic, but recently some prospective studies, including 2 randomised controlled trials have been published. What does the evidence tell us about these devices? Are they ready to enter the mainstream of addiction treatment? In this seminar Richard Hallinan will present a brief overview of the published literature, and Ross Colquhoun will describe and present data on his experiences using naltrexone implants in Sydney over a number of years. In the second half several case studies will be presented, with discussion.

Pre-reading: http://www.redfernclinic.com/concord/2009/12/concord-seminar-series-tues-1st.php4

20/04/2010 - Wet Brain: Alcohol and the Brain - delirium, confabulation, amnesia, and collapse. Professor Paul Haber.

In this seminar Dr Paul Haber will take us through alcohol's wide range of acute and chronic neurological neuropsychological harms, with an emphasis on diagnostic dilemmas, problems not to be missed, harm reduction measures, safety issues and other pitfalls in community practice. Case studies of collapse, confusion, memory loss, and gait impairment will illustrate the importance of alcohol as one of the "great mimics" of modern medicine.


8/06/2010 - The Other Hepatitis - An Update on Hepatitis B Part 2. Dr Gail Matthews, Infectious Diseases Physician, St Vincent’s Hospital, Darlinghurst


Although less common in injecting drug users than Hepatitis C (HCV), Hepatitis B (HBV) is common in Australia, and co-infection with Hepatitis C poses particular problems. Part 1 of this seminar pair looked at trends in the epidemiology of Hepatitis B in Australia, how to assess and manage Hepatitis B and to prioritise for treatment, as well as about new directions in pharmacotherapies. By popular demand from participants in the first seminar, we will revisit these themes with more case studies covering diagnosis and assessment, indications for treatment, coinfection with HCV or HIV, and special issues for substance using populations.

For pre-reading:
http://www.redfernclinic.com/concord/2008/07/other-hepatitis-update-on-hepatitis-b.php4


3/08/2010 - Is pathological gambling an addiction? You bet it may or may not be! Prof Alex Blaszczynski

Pathological Gambling is classified in DSM IV among the impulse control disorders, yet it appears to share many features with, and its diagnostic criteria modelled after, substance use disorders. What do they have in common, and can drug and alcohol services have a role in dealing with the problem? Do medications help? How should drug and alcohol specialists handle people with concurrent substance use and gambling problems? Can Protective Estates Orders be invoked? Cases studies will present gambling problems in isolation and in combination with substance use problems. Alex Blaszczynski is a Professor of Clinical Psychology and the Director of the Gambling Treatment Centre in the School of Psychology, University of Sydney and was Head of the Department of Medical Psychology at Westmead Hospital. He has conducted randomized controlled outcome cognitive and behavioural treatment studies, and investigated the prevalence of co-morbid substance abuse, withdrawal and tolerance phenomenon, and suicidality in pathological gamblers seeking treatment. He has written a self-help manual, "Overcoming Compulsive Gambling". He is editor of International Gambling Studies and Assistant Regional Editor for Addiction. http://www.psych.usyd.edu.au/staff/alexb/

21/09/2010 Mentally Disordered or Mentally Ill? The NSW Mental Health Act, and how to use it in drug and alcohol settings and in community practice. Dr Glenys Dore and Dr Lisa Juckes.

In this seminar Dr Glenys Dore and Dr Lisa Juckes will take us through the maze of the NSW Mental Health Act, including the Temporary Protection Order, Continuing Treatment Order, the role of the Crisis Team of the local Mental Health Unit, the Mental Health Review Tribunal, and Community Treatment Orders, with a special emphasis on their use in people affected by alcohol and other drugs. There will also be a brief introduction to Protective Estates Orders and the workings of the Protected Estates Act 1983. Case studies will illustrate how these laws and regulations are best used in community practice and drug and alcohol settings.


30/11/2010 - The Exit Strategy Part 2: Is there life after methadone? Dr Nick Lintzeris & Richard Hallinan

A common complaint about opioid substitution treatment is that there is "no exit strategy". People talk of liquid handcuffs, and critics claim OST just keeps the people addicted forever. How should the health professionals respond to a request for reductions toward abstinence? Is there any evidence to guide professional practice? Dr Nick Lintzeris (and Richard Hallinan) will present an overview of published evidence about duration of OST treatment, withdrawal and reduction regimens, "cycling in and out of treatment", the relative ease of reductions for methadone and buprenorphine and other matters. Case studies and discussion in the second half.

Concord Seminar Series – Tues 1st December 2009.

Collegial debate: What is the drug of first choice for opioid dependence?

In this seminar we had four cases "for the sake of argument" as to what should be the drug of first choice for opioid dependence.

Richard Hallinan first argued the case for buprenorphine.

The first point is buprenorphine's similar efficacy and cost effectiveness compared with methadone. Systematic reviews show retention in treatment was superior for flexible MMT over flexible BMT dosing but no significant difference in opiate use; overall MMT was slightly more effective and less costly than BMT (Connock et al 2007; Mattick et al 2008, Cochrane).

Lower retention may reflect an advantage of buprenorphine, the ease of reductions & withdrawal. Buprenorphine had the highest cost effectiveness for inpatient or outpatient withdrawal management of the modalities examined in the NEPOD studies (Shanahan et al 2006); and the ease of reductions/withdrawal in short term dosing 1-4 weeks is endorsed in a Cochrane review (Gowing et al 2009). Buprenorphine has great flexibility as a "gateway" treatment, whether to abstinence, naltrexone (O’Connor et al 1997; Collins et 2005; Umbricht et 1999), or MMT.

The third major point is buprenorphine's greater margin of safety than methadone, reflected in low mortality rates in BMT in France despite liberal availability and unsupervised dosing for a number of years. “Indirect comparison of data from population cross-sectional studies suggests that mortality with BMT may be lower than that with MMT" (Connock et al 2007). In a 10 year longitudinal follow-up of participants in a randomized trial of MMT vs BMT there was no significant difference in mortality by treatment group (Gibson et al 2008). NSW data following up all MMT and BMT starts showed "Despite shorter retention in treatment, buprenorphine maintenance was not associated with higher risk of death." (Bell et al 2009).

Buprenorphine has fewer & less severe side effects and drug interactions compared with methadone. QT prolongation is not associated with buprenorphine, and pharmacokinetic interactions are less troublesome, partly because of the wide safety margin of buprenorphine itself. Sexual side effects appear to be lower with buprenorphine. Most importantly, sedation, especially with benzodiazepines, is less. (Lintzeris et al 2006, 2007)

A further argument in favour of buprenorphine as first line treatment is that a stepped care model starting with buprenorphine progressing to MMT has been shown to be non-inferior to standard MMT (Kakko et al 2007, 96 self-referred subjects randomised). Outcomes were virtually identical for retention in treatment and proportion of urine samples free of illicit drugs. Among completers of stepped therapy, 46% ultimately remained on buprenorphine/naloxone.

A number of RCTs show equivalence of second daily or thrice weekly dosing to daily dosing. Less frequent attendance has greater acceptability to patients, and there is reduced need for take-home or unsupervised doses, reduced risk of diversion, and potentially greater public and political acceptability of this treatment.

Finally there is the existence of a formulation of buprenorphine less attractive to injectors, buprenorphine/naloxone. “Most (68%) had tried the buprenorphine +naloxone combination IV, but 80% said they had a "bad" experience. Its street price was less than half that of buprenorphine alone.” (Alho et al 2006). “In the year after its introduction in Australia, BNX was injected less frequently and by fewer regular IDUs and clients compared with BPN” and compared with methadone. (Degenhardt et al 2009, IDRS, 2003-2007, adjusted for sales).

RH concluded: "What I am not saying: is that buprenorphine is "better". But why would you NOT choose as first line treatment a medication of similar efficacy and cost effectiveness, greater safety, better side effect profile, lower drug interactions, greater ease of reductions, and greater public acceptability than MMT, which gives equivalent results in a stepped care model to standard MMT? "

_________________________________________________

Prof Nicholas Lintzeris next argued why sustained release oxycodone (or indeed sustained release morphine, now available in twice daily and even once daily formulations) would be the ideal drug for opioid maintenance treatment. This is admittedly hypothetical since current NSW law only allows oxycodone hydrochloride for pain indications in non-dependent patients except under specific authority from PSB.

Prof Nicholas Lintzeris gave the case for oxycodone based on:

# Pharmacological principles (sustained delivery, avoiding peaks and troughs, possibly even superior in this respect to methadone which can fluctuate widely within a 24 hour period and sometimes needs twice daily dosing to avoid emergence of withdrawal symptoms).
# Side effects (there may be less constipation and sweating than with methadone)
# Overcoming demand problems (these medications are already preferred by many, if not most, opioid dependent people, on grounds of greater predictability and safety and lower cost, compared with heroin).
# Overcoming supply problems (any doctor can feel comfortable prescribing these medications, as they already do so for pain, provided they adhere to risk management strategies; the risks and difficulties associated with long half life agonists - accumulations and overdose - do not apply).
# Stigma (methadone has a stigma which discourages many people from entering maintenance treatments).
# Do-it-yourself injectables clinic.

There is an existing, albeit limited evidence base regarding the use of slow release oral morphine to treat opioid dependence (e.g. see Mitchell, White et al 2004 - below), demonstrating the such approaches are feasible. In Austria, oral morphine is a licensed and available treatment approach for opioid dependence, and accounts for approximately a third of treatment places. An important step forward however for more widespread uptake of this approach is development of abuse deterrent preparations that reduce the risk of injecting formulations.

_____________________________________________________________

Richard Hallinan then put the case for naltrexone. Naltrexone is the most direct path to abstinence, the gold standard treatment outcome. It has minimal side effects, no opioid side effects, minimal drug interactions, is non dependency forming, reduces opioid craving, and it’s easy to stop.

Naltrexone also has other therapeutic benefits including effectiveness in reducing alcohol consumption (Cochrane standard evidence), effectiveness for weight loss (especially in combination with bupropion) and effectiveness to reduce amphetamine use (Jayaram-Lindstrom et al 2008 RCT n=80, vs placebo).

Naltrexone ought to be first line treatment, however currently it is manifestly not so, neither as doctor or patient preference. Low demand and uptake reflects low patient enthusiasm, poor retention, and in Australia the cost, as the treatment is unsubsidised. There are also difficulties of induction, including the high cost of rapid opioid "detoxification" as the preliminary step.

There is a lack of RCT evidence supporting oral naltrexone: poor treatment retention, and modest heroin use reduction compared with placebo, which was non-significant with adequate concealment. (Minozzi et al 2006, Cochrane review). There was also greatly elevated overdose risk due to poor treatment retention. “The relative risk of death for oral naltrexone subjects was 7.4 times (high-risk period, p < 0.0001) or 2.8 times (low-risk period, p = 0.055) that of methadone subjects.” (Gibson and Degenhardt 2007, see also Digiusto et al 2004, NEPOD).

Naltrexone is safe and effective if people take it. As the problem is compliance with oral naltrexone, naltrexone sustained delivery formulations should be the answer. Unfortunately, large scale use of naltrexone implants began in Australia before preclinical, phase 1, 2 or 3 studies were carried out. Various formulations and devices have been offered in different places, and at different times, with some doubts about uniformity of manufacture and good manufacturing practice accreditation over the years.

Even nearly a decade later, the published literature leaves the critical reader in doubt about the rate of serious adverse effects, the efficacy of implants (duration of adequate blood levels and inter-individual variability in blood levels), the risk of problematic use of other substances, and long term outcomes.

Retrospective and naturalistic studies for efficacy and safety, however, suggest probably higher safety from implant formulations compared with oral naltrexone, and at least comparable safety (in terms of mortality) compared with MMT and BMT.

In Western Australia, naltrexone implant treatment was associated with reduced opiate overdoses compared with pretreatment, but increased sedative and other drug overdoses and other drug related hospital admissions (Hulse et al. 2005, Ngo et al. 2008). In Queensland, a retrospective study from a single treatment centre found lower crude mortality but no significant difference in standardized mortality rate for naltrexone implant compared to BMT (Reece 2007). Similarly Tait et al. (2007) found age standardized mortality rate ratio for naltrexone implant vs MMT to be 0.65 (95% CI = 0.12–1.2 NS).

There have been two RCTs of the “GoMedical” naltrexone implant. Kunøe et al 2009 (n=56, 180 days) found lower heroin use, fewer days’ use compared with “normal after care”. Hulse et al 2009 (vs oral Ntx, n=70, 180 days) found lower self reported opiate use, but no difference in urine test confirmed heroin use; other drug use, especially non-heroin opioid use, was poorly assessed. The average duration of adequate blood naltrexone level was substantially revised downwards, compared with previous studies. The good news was that in neither study were there any deaths in patients who received implants.

RH concluded: "What I am not saying is that naltrexone is 'better'. But everyone deserves a chance at abstinence before being committed to agonist therapy, which leaves patients physically dependent on opioids with their considerable side effects, as well as being subjected to intrusions and restrictions on their lives, which may be for many years with no good evidence for how to end the treatment. The future of naltrexone treatment for opioid dependence must be sustained release naltrexone preparations."

____________________________________________________

Andrew Byrne, Redfern Surgery.

Methadone is the drug of choice for opioid dependence. Forty years of research prove that this therapy is effective in retaining patients in treatment, reducing illicit drugs use, lowering viral transmission and eliminating almost 80% of overdose deaths. None of these benefits has been shown to the same degree for buprenorphine and thus it should not be recommended as first line drug unless there are contraindications for methadone. Further benefits for those taking methadone is that it is safe in pregnancy and lactation while it is also more widely available both in Australia and around the world.

A possible increase in the overdose rate in the first two weeks of treatment is balanced by high numbers of drop-outs in the first two weeks of buprenorphine treatment. A recent large study in Norway showed two deaths in the first month of treatment out of over 3000 episodes in a seven year period.

However, patients make the choice about which drug much more often than doctors do (see below).

Cost effectiveness is far more positive with methadone, being an inexpensive non-patented drug. Common side effects are limited to constipation and sweating. More serious side effects can be limited by dose adjustments and hormone replacement when testosterone levels are suppressed. QT prolongation is common but appears to be of no clinical significance in isolation. Torsade de pointes tachycardia has only been associated with multiple risk factors some of which coincide with long-term survivors of opioid use, prescribed medications, alcohol and illicit drug use. Methadone has not been demonstrated to cause torsade and it is possible that higher doses make this less likely to occur. It is generally agreed that as with other drugs having a dose response, there should be no arbitrary limit on methadone dose levels.

Some references were detailed for the Concord audience.

RCT buprenorphine/methadone.

 Ling W, Charuvastra C et al.
 Mattick RP, Ali R, White JM et al.
 Kristensen O, Espegren O et al.
 Kakko J, Grönbladh L, Svanborg KD et al.
 Pinto H, Rumball D et al.
 Kamien JB, Branstetter SA, Amass L.
 Petitjean S, Stohler R, Déglon JJ et al.
 Cochrane Database of Systematic Reviews

Reasons for choosing MMT.
 Cost (cheapest drug around)
 Safe in pregnancy
 Available most widely (Aussie pts travel!)
 Highest retention rate
 Lowest illicit drug use rates
 Safety when used under supervision
 Original and best known.

How many patients have already tried both methadone and buprenorphine? It seems that the majority of patients attending for opioid dependency treatment are now aware of both methadone and buprenorphine and most have a clear idea which is best for them. This is due to personal trial and error or else street talk of the properties of both. But is this all hypothetical? Doctors are in fact only rarely in a position to decide/advise between methadone and buprenorphine.

English GP study
 A pilot study for a randomized controlled and patient preference trial of buprenorphine versus methadone maintenance treatment in the management of opiate dependent patients. Dr Pinto in England was trying to prove that buprenorphine had benefits worth including on the NHS formulary for their area. Out of 42 subjects recruited, none agreed to be randomized. The reason was that all patients had a clear idea which drug they wanted and refused to consider alternatives in this trial setting.
Pinto H, Rumball D, et al. Journal of Substance Use 2008 13;2:73-82

World’s largest study on OTP.
 Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, Degenhardt L. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009 104;8:1363-1372

Burns et al. abstract quotes:

 “the hazard of leaving treatment was 1.9 times for those on buprenorphine relative to those on methadone”
 “This study has provided population-level evidence to suggest that retention in methadone and buprenorphine differ in routine clinical practice.” (retention in methadone was much better).


Things go better with methadone!

 Much lower diversion rates (anecdotally)
 No substantial problems with contaminated drug being injected (unlike buprenorphine).
 Less “revolving door” syndrome as with buprenorphine (see Burns’ latest study).

Best drug for addiction Rx.
 Do you want your patient to have the best chances of getting their lives together, staying in treatment and avoiding illicit drugs?
 Of course you do!
 Then you should recommend methadone as a first option when there is a choice.

Is this debate “for real”?
 Would we be having this debate about antibiotics, antidepressants or hypertension drugs?
 Of course not!
 **Treatment matching** is the way to go. [Which brings us to the case studies presented in the second half (see below)]
 Dependency medicine has a way to go, too!

_______________________________________________________

Post Script

RH introduced several intentional errors/dubious claims in his presentations, some of which were identified by participants, and others swallowed whole, perhaps owing to the poker faced delivery.

There is no good evidence that naltrexone reduces opioid craving.
Evidence that sexual side effects are lower with buprenorphine is weak, and there is no research for women.
Second daily or thrice weekly buprenorphine dosing in clinical practice seems to suits only a minority.
Naltrexone alone, without bupropion, has small effectiveness for weight loss.
RCT evidence does not support claims for greater safety for buprenorphine (but as NL pointed out, safety for 3rd parties, especially children, is certainly greater for buprenorphine).
There is no evidence that reductions over a longer period are easier for buprenorphine than methadone, and 2 studies sometimes cited to support the claim short term ease of buprenorphine reductions compared with methadone compared a buprenorphine + carbamazepine regime to an methadone + carbamazepine regime. Carbamazepine is a powerful inducer of the metabolism of methadone. (Seifert et al 2002, 2005)

_________________________________________________


Concord Dependency Seminar November 2009, Treatment Matching - Case Studies

Kyle, a 19 yo heroin user, has been smoking heroin since age 16, daily for the last year, and recently he started injecting it. He used MDMA on weekends from age 16, seldom drinks alcohol or smokes THC, but smokes cigarettes. He has previously "dried out" several times using his mother’s Serepax, but stayed clean for only 3-10 days. He is a student at uni doing arts/law, and lives with his parents. He has maxed out credit card, has stolen money from his parents, used up all a private inheritance from his grandfather who died 3 years ago ($40,000).

Kyle feels he has lost control. He badly needs money, and feels he may have to work as a prostitute. He doesn’t want anyone to know he is using heroin, and is terrified his step-father (a public prosecutor) will find out. He can’t go away or do a rehab for this reason, and anyway he is in the middle of term with exams in 6 weeks. He asks for medications so he won’t have to use heroin.

What treatment is first choice for Kyle?

Comments: a show of hands gave majority support for buprenorphine for this patient, owing to his current predicament, and the short duration of his opioid dependence. He might use buprenorphine for withdrawal management and go onto maintenance if needed. Ross Colquhoun (who will present his experience with naltrexone implants in the Feb 2010 Concord seminar) felt this patient would do very well with naltrexone implant, but this would be too disruptive currently and he should be stabilised on buprenorphine first. Cost would probably also be a major problem.

_______________________________________________


Robbie is 41 yo, and has been a disability pensioner for 15 years for "mental health problems", including psychosis. He has been an involuntary inpatient for extended periods, including 6 months last year, and his community treatment order has ended. He is no longer getting depot flupenthixol. Two recent hospital admissions under the mental heath act were for aggression/violence. He comes asking for treatment because he has been hanging out, says he has been using $200/day of heroin (he says he has a neighbour who is a dealer). He says he was on MMT once before for 18 months but didn’t like it. Sometime he does inject BM methadone.

On examination he is in classic opioid withdrawal, and has plenty of old scars and recent tracks.

A call to the local mental health service confirms his psychotic episodes have often been precipitated by alcohol or, apparently, amphetamines. He also uses benzodiazepines and cannabis, according to previous history and urine toxicology.

What treatment is first choice for Robbie?

Comments: a show of hands gave majority support for methadone for this patient, owing to his psychotic illness and the antipsychotic properties of methadone. Retention in treatment might be an issue with buprenorphine given his previous poor compliance with antipsychotics. However, doubt was cast on the history of heroin use, as it seems unlikely a long standing disability pensioner for "mental health problems" would have the capacity and resources to afford $200/day. Induction onto methadone would have to be very cautious. It was noted that amphetamine intoxication could potentially be confused with opioid withdrawal. Naltrexone treatment was generally considered inappropriate.

_______________________________________________


Emma is 36, and a business analyst working for a merchant bank. She is single, works hard and plays hard, and loves having the freedom to party. But partying has got a bit out of control. She admits to near daily drinking (60-90g/day for several years), & occasional use of cocaine on the weekends. There is also frequent use of over-the-counter and prescribed codeine (40-120mg/day) and oral amphetamines as a "pick me up" during the week.

3 months ago Emma was introduced to heroin. She has recently injected it a few times and now is afraid she might be getting a habit. She wakes up craving heroin, can’t get it off her mind, and uses codeine to get through the day. She finds heroin really helps with her severe period pains and wonders about getting a hysterectomy. The heroin use worries her because she doesn’t want to be addicted. She despises junkies and is appalled by the idea of methadone.

What treatment is first choice for Emma?

Comments: the majority view was that alcohol was her primary problem, and her other drug problems (use of codeine and amphetamines for hangover) might be more easily controlled if she could achieve alcohol abstinence. An inpatient opioid/alcohol withdrawal management and a period of residential rehabilitation, or intensive outpatient counseling supported by alcohol pharmacotherapy would be the best option if she were prepared to try it.

However, if opioid maintenance was needed, a show of hands gave majority support for buprenorphine for this patient, owing to her resistance to methadone and the possibility that alcohol use might be less problematic if she were on a partial agonist. However the gynaecological problems need assessment and management, and her chronic pain might make a full opioid agonist necessary. NL argued that this is exactly the sort of patient who would do well with supervised dosing of a sustained release opioid such as oxycodone, which might be justified for her chronic pain, and which she would probably find more acceptable than methadone or buprenorphine. Ross Colquhoun felt this patient would do very well with naltrexone implant, which would also help with her alcohol problem.


Ref 1.
Mitchell TB, White JM, Somogyi AA, Bochner F. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction. 2004; 99:940-5

Concord Seminar Tuesday 4th August 2009.

Mechanisms and Treatment of Alcohol Dependence and its Sequelae: a 2009 Update

Dr Saunders used a single, complex case of alcohol dependence to introduce an overview of neurobiological mechanisms underlying the development of dependence; and a case of fetal alcohol syndrome, as an example of alcohol related neurodegeneration.

Patient K was a woman in her early 40s who had lost a promising professional career and marriage in her late 20s after a severe neurological insult left her with cognitive impairment, gait disturbance and dysarthria. Five years later she had married again and entered into a new phase of life, but gradually developed alcohol dependence with regular consumption of 120-180g/day. Among risk factors were a family history (father) of alcoholism, and the trauma and loss resulting from her disability and possibly also the brain injury itself. Treatment followed a not unusual course of withdrawal management followed by periods of abstinence supported by acamprosate and/or naltrexone, each time with subsequent relapse.

Twin studies show about 50% of population variance of alcoholism to be genetic; there is a tendency to father-son and mother-daughter vectors. Cohort longitudinal studies point to developmental factors especially childhood abuse, be it physical, sexual, or repeated mental abuse, along with other trauma, for example PTSD. At a sociological / anthropological level, cultural, socioeconomic and regulatory factors are also important.

What are the mechanisms of dependence? While workers in the field of addiction are becoming fairly familiar with the idea of meso-limbic reward pathways, our speaker gave us a more comprehensive understanding of the neurobiological mechanisms of dependence by including also mesolimbic stress, and frontal inhibitory, control systems.

Among the neuronal reward circuits, dopaminergic pathways are especially important for psychostimulants and nicotine, and opioid pathways for alcohol and opioids. When such substances are repeatedly or continuously used, the natural activity of these systems is suppressed. A negative mood and motivational state develops: more and more of the substance is required merely to maintain the normal state, while other normally "rewarding" activities become blunted. The substance use can be said to have “high-jacked” the reward system.

At the same time, with repeated substance use the balance is re-set between brain stress and anti-stress systems, through stimulation of pathways involving the excitatory neurotransmitter glutamate and CRF (corticotrophin-releasing factor) and suppression of GABA and ‘Neuropeptide Y’ circuits. The stress systems become “supercharged” to respond to exposure to psychoactive substances and cues or trigger for the substance use.

Finally, with repeated substance use there is progressive impairment of pre-frontal-mesolimbic inhibitory pathways, with impairment of executive functioning, decision-making and insight.

In combination, suppression of reward systems, their "high-jacking” by substance use, and “supercharging” of the stress systems to respond to psychoactive substances and their associated cues, generate a powerful “internal driving force” which is little influenced by voluntary control, because of impaired frontal inhibitory systems.

At this Concord Seminar, when an audience member asked about the situational and emotional triggers for alcohol use in patient K, Dr Saunders responded: "It doesn't matter what the triggers are, she is dependent. There is an overwhelming, tsunami-like force driving it."

Pharmacotherapies for alcohol dependence, included much the same list as when Dr Saunders last spoke to us in 2005, though the evidence base has developed since then.

 Naltrexone (blocks opioid pathways for alcohol reinforcement/reward; see below)
 Acamprosate (restores balance to GABAergic/glutaminergic stress responses; see below)
 Topiramate (similarly, restoring balance to GABAergic/glutaminergic pathways in the corticomesolimbic system; several randomised trials from USA, and Finland)
 Disulfiram (aversive agent, unpleasant reaction on alcohol ingestion; see below)
 Ondansetron (selective 5-HT(3) (serotonin) antagonist [‘Zofran’] may be effective for patients with early-onset alcoholism, associated with greater serotonergic abnormality & greater mood disturbance, including depression, anxiety, hostility and antisocial behaviors)
 Baclofen (GABA-B receptor agonist, reducing craving and alcohol intake in small trials)
 Buspirone (for alcohol dependence and comorbid social anxiety)
 SSRIs (for underlying or residual depression, and to be avoided in young alcoholic men with depression/suicidality, in whom they may make matters worse – the reason for this is not entirely clear, but see ondansetron above)

While a Cochrane review (Srisurapanont et al, 2005) for naltrexone gives clear evidence that relapse into alcohol dependence is reduced by some 36%, the Cochrane review of acamprosate has not yet reported, and there have been negative findings from recent US and Australian studies. There have been two important studies of combined naltrexone and acamprosate for alcohol dependence, with some evidence of benefit from the combination in Kiefer et al (2003) but little at all for acamprosate from the COMBINE Study (eg Anton et al 2006; Donovan et al 2008). There is also good evidence for improved outcomes for disulfiram, provided it is supervised.

With huge variability in findings from different studies, especially for acamprosate, Dr Saunders notes that exploring the heterogeneity of these studies may be a key for furthering our understanding and planning further research. Much may be lost by the reductionism of meta-analysis. Meanwhile, naltrexone tends to be his first line choice for alcohol dependence.

Some basic contrasts between the use of naltrexone and acamprosate are listed here.

Initiation: for naltrexone, when abstinent or when drinking; for acamprosate only when abstinent.
Onset of action: for naltrexone within 24 hours; for acamprosate one week
Pattern of drinking: for naltrexone, alcohol dependence with binge pattern; for acamprosate, alcohol dependence with regular daily drinking
Triggers to drink: for naltrexone, smell, taste, initial consumption of alcohol; for acamprosate, geographical, interpersonal and emotional triggers
Sub-type of dependence: for naltrexone, early onset & strong family history; for acamprosate, later onset.
Genetic markers: for naltrexone, having opioid receptor gene (OPMR1- Asp40 allele)

_______________________________

We were then introduced to a difficult clinical situation. An addiction specialist noticed by chance, while treating a pregnant alcoholic woman abstinent in early recovery, that a previous child had previously unrecognised fetal alcohol syndrome. Ethical issues about contacting that child’s doctor, or community services, the potentially devastating impact of informing this woman at such a time and almost certainly precipitating relapse and worse outcomes led to lively discussion. Happily in this case the fine line was successfully trod.

Fetal Alcohol Syndrome is at the most severe end of the range of Fetal Alcohol Disorder Spectrum (FASD). The features are
1. maldevelopment of the mid face, including a small flattened nose, wide-set eyes, epicanthic folds, a thin upper lip, and absent philtrum
2. microcephaly, mental retardation (average IQ 70) and behavioural abnormalities
3. congenital cardiac abnormalities

Learning difficulties become apparent in childhood, and there is no improvement in IQ over time. There are social interaction deficits, but more typically the children are over-friendly to peers and adults, and so-called moral deficits – high prevalence of promiscuity, sexually transmitted diseases in teen years - may be attributable to these factors.

Management consists of teaching adaptive living skills, (such as to be appropriately guarded with strangers and certain family members), educational placement, speech and language services, occupational therapy and vocational guidance, and advocacy as needed.

This brought us to the matter of alcohol and neurodegeneration, especially in young people. We are reminded that brain development continues until at least the age of 21. Particularly that during this time, but also afterwards, neurones and their connections are in a state of dynamic flux, of which ongoing neurogenesis is an essential part.

In experimental animals, with increasing alcohol exposure there is increased differentiation of neural stem cells to oligodendrocytes and astrocytes and reduced differentiation to neurones, with blunting of dendrites, and inhibition of neurogenesis as a primary mechanism of neurodegeneration. In Fetal Alcohol Syndrome there is not only major structural damage in the 1st trimester but a quantitative decline in the number of neurones in the 3rd trimester through inhibition of neurogenesis (in which tobacco smoking, diet and vitamin deficiencies probably also play a role).


For further reading, we recommend Bankole Johnson's review:

Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.Biochem Pharmacol. 2008 Jan 1;75(1):34-56. Full text available free at http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=17880925


Also, Dr Saunders won't mind us giving a plug for a new "concise and practical guide for students and practitioners of medicine and other health professions who come into contact with people with substance use disorders." Addiction Medicine. Editors Noeline Latt, Katherine Conigrave, Jane Marshall, John Saunders, E. Jane Marshall and David Nutt. Oxford University Press. ISBN13: 9780199539338

Concord Seminar Tues 3rd February: "Opioid Side Effects - Part 2".

Professor Nick Lintzeris gave us a tour through the research on methadone side effects, pointing out the major deficiencies in the methodology of just about every study. There is so little good research on the most common side effects, sweating and constipation, that he decided to omit them altogether. [We had a previous talk on these subjects at Concord and generic advice seems to apply: eg. diet, exercise, dose adjustments, etc.] The other major side effects raised by our speaker were hormonal imbalance, osteoporosis, sleep apnea, cognition and cardiac rhythm disturbances.

To put the issue into perspective, we were told that the broad outcomes from buprenorphine and methadone were similar but with (1) significantly better retention for methadone (= fewer drop-outs) but (2) fewer reported side effects for buprenorphine. There was also a trend for less heroin use in methadone versus buprenorphine prescribed patients.

The relative merits of the two licensed drugs for opioid maintenance may be less relevant today when most patients have a clear preference before coming into treatment. A major influence on this decision was the patient’s side effects from one drug or the other. Such matters were emphasised by an interesting ‘7 Boroughs’ study from the Maudsley (London) in which our speaker was an author (n=182). Another trial of new patients going onto maintenance treatments in England found that there was not one volunteer in a year who agreed to be randomised to one of these two drugs (Ref 1). They all knew what they wanted from experience.

An intriguing power point slide summarized results from a trial from Malaysia showing high rates (30-50%) of urinary hesitancy, constipation, drowsiness and sweating from buprenorphine (Schottenfeld et al). In practice these are rarely seen in the Australian context and one wonders if, like Fanoe’s study on syncope the responses were exaggerated by the nature of the questions, questioning or questioners (or the translation). Fanoe uniquely found 10-30% syncope histories in buprenorphine/methadone patients in Denmark.

Regarding endocrine abnormalities it was pointed out that all opioids affect the hypothalamic and peripheral hormone systems, most notably testosterone in men on methadone. Long periods of low testosterone can lead to altered calcium metabolism, osteopenia and in the longer term, osteoporosis. Two studies were quoted showing high rates of both lack of libido as well as erectile dysfunction in men on methadone (more so than with buprenorphine). We were told that depression, pain and fatigue can result from the low testosterone as well as sexual disturbances. One study showed major hypogonadism in buprenorphine patients, (Colemeco), something which is not consistent with other experience. Another study (Kim et al.) showed high rates of established osteoporosis and osteopenia in long term methadone patients. The roles of testosterone replacement, oestrogen, calcium and vitamin D were discussed briefly.

There seemed to be a consensus that a one-off measurement of total testosterone (morning specimen is best) was a reasonable measure for all men on methadone. More detailed examinations were justified when there were suspect symptoms (eg. prolactin, oestrogen, thyroxine, etc). Investigation for osteoporosis was more contentious, as for testosterone replacement therapy which has various guidelines, recommendations and PBS prescribing rules. An endocrine opinion can be very helpful in such cases.

Sleep apnea has been presented as a looming problem at conferences recently. One small study showed quite worrying results from Weston Hospital in Melbourne. Fatigue and snoring may be the only signs yet sleep studies may show major disturbances including low oxygen and high CO2 levels for extended periods. As with other studies, major methodological problems occur commonly but it was proposed that some otherwise unexplained deaths in methadone patients may be due to sleep apnea. However, as with QT problems, unexplained deaths in methadone/bup patients are exceedingly rare.

Professor Lintzeris then handed out a copy of a journal reprint to all participants. We may have been caught out by chronology since his information implied that these were official American guidelines to address cardiac safety in methadone maintenance treatment. Since December, however, this rather contentious article has been withdrawn and republished in at least two more ‘internet’ versions by the Annals of Internal Medicine. Krantz and colleagues recommended ECGs on all patients before treatment and at 3 months and annually despite most experts (including Krantz himself in 2006) saying that routine ECGs were not needed. The recommendation does not have the official backing of CSAT (the official American health authority in this area). More embarrassing still for the authors, a number of expert contributors ‘declined to be acknowledged’ in the final paper, nor were some major potential conflicts of interest declared until the third version.

This unusual publication story is now neatly balanced in an excellent editorial by Gourevitch from New York (Ref 2). In it he notes that torsade de pointes tachycardia is rare and typically associated with ‘exceptionally high doses of methadone’ and/or other risk factors for dysrhythmia. He says that more information is needed before cardiographs could be recommended as a safety strategy, favouring as he does an approach based on individualised clinical assessments, just as would be done for any other rare but potential serious complication.

Consistent with long standing NSW Health Department policy, those on high doses (>150mg daily) as well as those with other risk factors (HIV, co-medication, >40 years, female sex) should be considered for baseline ECG. Alcohol and cocaine are also strongly implicated in some reports. Of almost 80 torsade cases in the literature I could find only one single death (a female patient aged 47 who had a myocardial infarction and torsade arrhythmia). It still appears that this cardiac complication is either rare or non-existent in young people starting on standard methadone treatment programs.

Professor Lintzeris’ title slide stated: “Side effects to methadone: should we be bothered?” The side effects from street drug use are so legion that it is may be easy to overlook unwanted consequences of effective treatment. But this is not what good medicine is all about.

Comments by Andrew Byrne based on the Concord Seminar talk, power point slides and pooled references with contributions from Richard Hallinan and Judith Meldrum with thanks.

References:

1. Pinto H, Rumball D, Maskrey V, Holland R. A pilot study for a randomized controlled and patient preference trial of buprenorphine versus methadone maintenance treatment in the management of opiate dependent patients. Journal of Substance Use 2008 13;2:73-82

2. Gourevitch MN. First Do No Harm ... Reduction? Annals of Internal Medicine 2009 150;6 (Annals on line http://www.annals.org/cgi/content/full/0000605-200903170-00111v1 )


Clinic web page: http://www.redfernclinic.com/#news

3/02/2009 Opioid Side Effects - Part 2. Nicholas Lintzeris
7/04/2009 Smoking cessation update. Renee Bittoun
2/06/2009 TBA (cancelled)
4/08/2009 Alcohol problems. John Saunders
6/10/2009 Prescription opioids in chronic pain. Dr Alex Wodak & Dr Milton Cohen
1/12/2009 "The great debate" What is drug of first choice in opioid addiction? Dr Nick Lintzeris says oxycodone; Dr Richard Hallinan says buprenorphine; Dr Andrew Byrne says methadone.

ARCHIVE OF SUMMARIES (OTHERS SEARCHABLE ON SITE)

"Opioid Side Effects - Should we be bothered?"
http://www.redfernclinic.com/concord/2009/03/concord-seminar-tues-3rd-february.php4
3/2/09

Comparisons from UK, Victoria and NSW. http://www.redfernclinic.com/concord/2008/02/comparisons-from-uk-victoria-and-nsw.php4
5/2/08

Practising in Addiction Medicine: how not to be sued!http://www.redfernclinic.com/concord/2008/03/subject-practising-in-addiction.php4
18/3/08

Treating the Addicted Brain: Agonists, Antagonists and Modulators. http://www.redfernclinic.com/concord/2008/05/treating-addicted-brain-agonists.php4
20/5/08

Adult ADHD & Substance Use Disorders – Dr Julian Trollor
http://www.redfernclinic.com/concord/2008/07/adult-adhd-substance-use-disorders-dr.php4
22/7/08

Amphetamine/Stimulant Use: Presentations, complications, interventions.
http://www.redfernclinic.com/concord/2007/01/amphetaminestimulant-use-presentations_30.php4
30/1/07

Methadone side effects, separating fact and fiction.
http://www.redfernclinic.com/concord/2008/03/methadone-side-effects-separating-fact.php4
20/3/07

The Interpretation of Urine Toxicology in Dependency Treatment. Principals and Pitfalls.
http://www.redfernclinic.com/concord/2007/05/interpretation-of-urine-toxicology-in.php4
22/5/07

Personality Disorders. 31 July 2007
http://www.redfernclinic.com/concord/2007/07/personality-disorders-31-july-2007.php4
31/7/07

Personality disorders (by Dr Glenys Dore) supplementary notes.
http://www.redfernclinic.com/concord/2008/07/personality-disorders-by-dr-glenys-dore.php4
31/7/07

Withdrawal management and detoxification-with a focus on complicated patients.
http://www.redfernclinic.com/concord/2007/09/withdrawal-management-and.php4
25/9/07

Advances in assessment and treatments for infection with hepatitis C virus (HCV)
http://www.redfernclinic.com/concord/2007/11/advances-in-assessment-and-treatments.php4
20/11/07

Welfare to Work, Implications for your Patients.
http://www.redfernclinic.com/c/2006/06/welfare-to-work-implications-for-your_2495.php4
30/5/06

Dependency issues and pain management - "A Busman's Holiday and Other Stories" http://www.redfernclinic.com/c/2006/08/dependency-issues-and-pain-management_9514.php4
25/7/06

Opioid Maintenance: Back to Basics. Therapeutic lessons from Vioxx and LAAM.
http://www.redfernclinic.com/c/2006/11/opioid-maintenance-back-to-basics_9619.php4
26/9/06

Dependency issues in gaols, juvenile justice and drug courts http://www.redfernclinic.com/c/2006/11/dependency-issues-in-gaols-juvenile_7874.php4
21/11/06

The use of anti-craving drugs for alcohol dependence.
http://www.redfernclinic.com/concord/2008/02/use-of-anti-craving-drugs-for-alcohol.php4
4/2/03

Dental problems in addiction treatment subjects. Does methadone rot teeth? Can we prevent dental decay?
http://www.redfernclinic.com/c/2003/05/dental-problems-in-addiction-treatment_20.php4
20/5/03

Smoking cessation in dependency patients / Therapeutic thresholds in methadone maintenance
http://www.redfernclinic.com/c/2003/09/smoking-cessation-in-dependency_23.php4
23/9/03

Concord Dependency Seminar Tuesday 23 July 2008 "The Other Hepatitis" - An Update on Hepatitis B. Dr Gail Matthews, St Vincents Hospital Darlinghurst

Summary Part 1. Epidemiology, natural history, assessment.


This seminar was titled The Other Hepatitis, reflecting the lower prevalence of Hepatitis B compared with Hepatitis C among people using addiction treatment services, and the lower profile of HBV in the community.

In contrast to the vigorous response in recent years to hepatitis C (HCV) in Australia, the response to hepatitis B (HBV) has lagged behind, despite important recent developments in understanding of HBV, in diagnostic tests and antiviral treatments, and desite its large disease burden, especially chronic liver disease and liver cancer.

There are many contrasts between HBV and HCV. Whereas HCV in Australia consists of two 'epidemics' - an older group of people born overseas in endemic areas and a younger group of injecting drug users - about half the prevalence of HBV is among Australians born overseas in endemic areas, especially China and SE Asia but also the Middle east and Mediterranean. Only 5% of chronic HBV is among IDUs; another 8% among men who have sex with men (MSM) and a staggering 16% among indigenous Australians.

The picture is different for new infections (incidence) of HBV in Australia: 44% of these happen among IDU (showing the importance of catch-up vaccination for non-immune people in this risk group) and 35% are through sexual transmission, disproportionately among MSM, but the majority still through heterosexual sex.

The total number of people in Australia with chronic HCV is fairly reliably estimated to be between 200,000 and 250,000, while estimates for HBV range more widely between 90,000 and 160,000, reflecting in part poor knowledge of HBV and low levels of testing among some of the high risk groups.

HBV is a DNA virus, where HCV is an RNA virus. HCV is essentially blood-to-blood transmission, particularly by unsafe injecting, and rarely by sexual transmission, while HBV is spread by contact with infected body fluids including blood, semen and saliva. HBV is thus sexually transmitted, but also by vertical transmission (mother to child), horizontally (close personal contact especially in childhood eg cuts, sores) and by IDU.

Of people infected with HCV, 20-30% spontaneously clear the virus, usually within 6 months, and regardless of their age at infection, without however developing immunity (ie they can be reinfected with HCV). Few people develop clinically evident acute hepatitis. By contrast, for HBV progression to chronic infection is strongly related to age at infection: 80-90% of children infected perinatally develop chronic HBV, with lower rates (30%) of chronicity after infection under the age of 5 years; only 6% of older children and adults develop chronic HBV. Most adults who are infected with HBV develop clinically evident acute hepatitis.

Unlike HCV where late clearance of the virus is unknown, a small percentage of people with chronic HBV clear the virus and develop immunity each year.

HBV and HVC are similar in that a subset of people develop chronic liver inflammation which may slowly progress to cirrhosis and liver failure in a minority of cases, and which increases the risk of development of hepatocellular carcinoma (HCC).

The diagnostic tests for HBV, and the natural history of the disease, while rather more complicated than for HCV, have become clearer in recent years. Chronic HBV is now though of as having 4 phases, with gradual progression through the first 2 phases "immune tolerant" and "immunoactive" into the third phase called "immune control" and sometimes progression into a fourth phase called "immune escape".

In the "immune tolerant" phase, there are high levels of HBV-DNA in the blood but little inflammation of the liver (so liver enzymes like ALT are low or normal). The body is not really fighting the virus. This phase is prolonged in people who get HBV perinatally (20 years or more) but is usually much shorter in adult infections.

In the "immunoactive" phase, DNA levels and liver inflammation (ALT) tend to fluctuate. The body is fighting the virus and the liver is in the wars. This can go on for many years, and this is when much of the liver damage from HBV develops.

If the body develops "immune control", viral DNA drops to undetectable levels and the liver function tests normalise. This phase can go on for decades and is associated with no progression of liver disease.

Unfortunately in some people HBV escapes from immune control. In the "immune escape" phase, viral DNA is detectable again and the ALT indicates liver inflammation. People in this phase of HBV often have the most seriously progressive disease.

In making a diagnosis of HBV and working out which phase a person is in, 3 types of tests are used: serological tests, liver function tests (especially ALT for inflammation), and viral DNA measurement (in Australia until recently only specialists could order this expensive test).

There are five commonly used serological tests for HBV. The surface antigen (HBsAg) indicates current Hepatitis B infection. It says "you have hep B now". It is found in serum during the incubation period before symptoms, and persists unless antibodies develop to the surface antigen (anti-HBs). Persistence of HBsAg defines chronic HBV and presence of anti-HBs indicates immunity to HBV infection (either by clearance of surface antigen, or by vaccination). Anti-HBs says "you don't have hep B and you can't get it anymore". * Sometimes anti-HBs wanes to undetectable levels in a person who has immunity to HBV, but there is still immune memory and anti-HBs rises to any immune challenge.

(* but see exceptions below)

The HBV core antibody (anti-HBc) develops early after HBV exposure and generally persists for ever: it just indicates previous exposure, and doesn't imply immunity (in this way it resembles HCV antibody). It says "HBV was here - and may still be here".

There are also tests for the HBV "e" antigen and its antibody (HBeAg and anti-HBe). HBeAg is a marker of viral replication and infectivity, and means there are high levels of HBV DNA in the blood. The person with HBeAg is either in the "immune tolerant" or the "immunoactive" phase of HBV. Loss of the HBeAg with appearance of anti-HBe generally indicates that the HBV DNA levels have been suppressed, the so-called "immune control phase" of hepatitis B - in this case the liver function tests will usually be normal.

However absence of HBeAg and presence of anti-HBe also occurs when a person moves into the "immune escape phase", where HBV-DNA levels and the ALT rise again.

Putting these tests together, HBsAg with HBeAg means chronic HBV with high infectivity. HBsAg with anti-HBe generally means low infectivity, undetectable DNA and "immune control" but can point to "immune escape phase", with high HBV-DNA levels and liver inflammation.

HBV is an oncogenic virus, and unlike HCV, can cause hepatocellular carcinoma (HCC) in the absence of cirrhosis. Of all people with chronic HBV, about 30% will go on to cirrhosis, and 5-10% will go on to HCC. Of people with HBV cirrhosis, about 1 in 4 will go on to liver failure within 5 years.

Numerous factors negatively influence HBV natural history and prognosis: host factors (male gender, older age, obesity and diabetes); viral factors (high viral load, genotype C); coinfection (HIV, HCV, hepatitis D); tobacco smoking and alcohol use. Mortality from liver failure or HCC is much higher when there is HIV coinfection.

Primary prevention for HBV depends on screening and vaccination of high risk individuals and universal vaccination of infants. People who may have poor immune response (HIV/haemodialysis patients) or who may be at higher risk (people with existing liver disease, health care workers) should have anti-HBs checked after the usual 3-vaccine course, and may need a booster. People, including infants, who have accelerated HBV vaccination schedules should also have a booster at 12 months. Immunocompetent people generally do not need boosters even if anti-HBs wanes. However, 5-10% of people fail to respond to vaccination, and these people should be advised that they may need passive vaccination with HBV immunoglobulin (HBIG) within 72 hours if they are exposed to HBV.

HBIG should be given to babies of HBsAg mothers within 12 hrs of delivery, and standard vaccination carried out.

The second part of this summmary will present treatment issues and case studies:

http://www.redfernclinic.com/concord/2008/07/other-hepatitis-update-on-hepatitis-b_31.php4

Concord Dependency Seminar Tuesday 23 July 2008 "The Other Hepatitis" - An Update on Hepatitis B. Dr Gail Matthews, St Vincents Hospital Darlinghurst

Summary Part 2. Treatment issues and case studies.

Dr Matthews pointed out that HBV is a fluctuating disease, and that for the majority, chronic HBV is never "cured". One might wish for HBsAg seroconversion as a goal of treatment, but this currently impracticable. For this reason it is best to think of and manage HBV as a chronic viral illness like HIV, rather than merely a viral hepatitis.

(Note: the majority of adults after acute infection, and a small percentage of people each year after chronic infection, may spontaneously clear HBV by developing anti-HBs. Usually this amounts to spontaneous "cure", however even then HBV can return in situations of immunocompromise eg HIV infection, chemotherapy).

Overall, about 60% of people with HBV can be managed by regular monitoring and attention to risk factors for disease progression, while 40% need antiviral treatment. However, people can move from one group to the other.

The goals of therapy can be defined in several ways, but the essential aim is virological suppression to allow histological improvement, and prevention of HCC and end stage liver disease.

For HBeAg positive individuals, a desirable end-point is anti-HBe seroconversion, with loss of HBeAg. For HBeAg negative individuals, suppression of viral DNA is the essential aim. For all individuals, normalisation of ALT is a good indicator of reduced hepatic injury.

Current therapeutic agents are divided into two types, immune modulators (alpha interferon) and antiviral agents (nucleoside analogues NAs). The development of pegylated interferons and a wider range of NAs has improved therapeutic options and outcomes.

The two main therapeutic questions are: whether to use an immune modulator vs an antiviral; and whether to use one or two agents (immune modulator plus NA, or two NAs).

The benefits of interferon alpha monotherapy for HBeAg positive patients are clear, with reduced rates of cirrhosis and HCC, and increased survival. The treatment aim is to "push" these people into the "immune tolerant" phase of HBV. The advantages of interferon are the finite duration of treatment, durable treatment response (when it occurs), the high rate of HBeAg loss (around 30%), and loss of HBsAg in 3%-8%. Drug resistance does not develop. Disadvantages include unpleasant side effects, high cost, and lower responses with some genotypes and where there is high-level viraemia.

Combination therapy with lamivudine plus interferon alpha for HBeAg positive patients gave higher end of treatment viral response but no higher rates of viral response, eAg seroconversion or sAg seroconversion, compared with interferon alone (Lau et al NEJM 2005).

Nucleoside analogues for HBV include lamivudine, adefovir, entecavir, telbivudine, tenofovir and emtricitabine (the first 4 are currently licensed for HBV). The archetypal NA, lamivudine, effectively suppresses viral replication, with reduced liver inflammation and improved liver histology. In up to 50% of HBeAg positive people, it also produces seroconversion to anti-HBe ("pushing" into the immune control phase) however this may take as long as 5 years. For people who do not achieve eAg seroconversion (ie do not develop anti-HBe) the therapy must be continued indefinitely, as it must also for people who are eAg negative (in the "immune escape" phase).

Unfortunately, viral resistance to lamivudine develops almost universally with time, especially where there is HIV coinfection. In this situation, alternatives are adefovir, and entecavir; the latter is a more potent suppressor of viral replication, and resistance appears to be less of a problem. It may increasingly be first line therapy for many people.

Nucleosides analogues have the advantages of oral delivery with minimal side effects. Treatment is less expensive than interferon, but not when given long-term. There is potential for multidrug resistant organisms, especially when NAs are used sequentially.

Management of chronic HBV depends on a thorough assessment including liver function, serological markers, HBV DNA, sometimes liver biopsy (or fibroscan), and cofactors for disease progression (HCV/HDV/HIV). People should be vaccinated for HAV, given clear advice on transmission, and problems of alcohol, tobacco, obesity and diabetes dealt with if possible.

Specific treatment is recommended for:
• HBeAg positive people who have elevated ALT, and HBV DNA > 20,000 IU/ml
• HBeAg negative people who have abnormal ALT, HBV DNA > 2,000 IU/ml, and necroinflammation/fibrosis on biopsy
• Cirrhotic patients with any level of measurable HBV DNA

Initial Treatment Strategies

Immune modulators may be preferred for healthy people < 60 years, with no cirrhosis, a baseline HBV-DNA > 1010 copies/mL, and ALT > 2-3 times normal, and who have genotype A or B (the more responsive genotypes)

Nucleoside analogs can be used for any age adult, for any genotype, with or without comorbidity (including cirrhosis with or without decompensation), a baseline HBV-DNA 109 copies/mL and ALT > 5 times normal.

In people with advanced HBV it is important to manage the viral infection aggressively and refer early for transplant assessment. Any patient with cirrhosis should have 6-monthly screening for HCC, using alphafetoprotein (AFP) and abdominal ultrasound (in cases of doubt triple phase CT/MRI). The following groups should also be targeted for HCC screening, regardless of their stage of liver disease: Asian men over 40 years of age; Asian women over 50 years of age; Africans over 20 years of age; and people with a family history of HCC.


Case studies (with apologies to Hanna Barbera)

Barnie is 36. He has a 12 year history of heroin injecting, previous buprenorphine maintenance on several occasions usually of short duration and with subsequent relapse His current BMT episode is 5 months, dose 8mg/day and he keeps using heroin.

He says "I've had hep B and hep C for years." He sometimes shares fits because 'What's the point? I've got both already." He drinks alcohol most days, 30-120g.

He is HCV seropositive and HCV-RNApcr positive; HIV negative and HBsAg positive. His ALT is 72, AST 60, GGT and other liver function tests are normal. After strong advice, he ceases sharing injecting paraphernalia, but he continues drinking most days.

On subsequent testing his ALT remains elevated. His second HCV-RNA pcr test is negative. He remains HBsAg positive, HBeAg positive and Anti-HBe negative. How should he be managed?

Comments: if his HCV-RNA remains negative, he may have ceased reinfecting himself with HCV and cleared the virus. He has "immunoactive" HBV with alcohol as a risk factor. Progressive liver fibrosis can occur in the "immunoactive" phase, and alcohol and periods of HCV infection may have contributed to this. Liver biopsy staging may be helpful here. If he does not have cirrhosis already, could have interferon treatment to try to push him into the "immune control" phase of HBV. He should be strongly encouraged and supported to stop alcohol entirely, and this would be a condition for interferon treatment. An alternative would be long term NA treatment.


Fred is 37 and has been on MMT for 6 years. He has not injected drugs for 5 years, and has practically given up alcohol, which he used to drink regularly 30-80g/day. He smokes 40 roll-your-own cigarettes a day.

He is HCV and HIV seronegative but has HBsAg, with both e antibody and antigen. He thinks he got HBV from injecting, but doesn't know when. His ALT and AST are usually normal or mildly elevated (<80) and other liver tests are normal.

During ketoconazole treatment for toenail tinea his transaminases rose to over 500, with other LFTs normal. He stopped the ketoconazole but his transaminases remained elevated (about twice normal) over the next 2 years. He remained positive for HBsAg, and anti-HBe, and became negative for HBeAg.

Fred is against "western" treatment for his liver, and gets herbal treatments from a homeopath in Victoria who runs a telephone consultancy. The cost of these medications ranges up to $60/month plus $60 for each phone consultation. Fred pays the phone bill.

Comments: when he had both Anti-HBe and HBeAg, he was apparently seroconverting for e antigen, thus follow up showed loss of HBeAg. As his transaminases remained elevated, HBV-RNA testing was subsequently done, showing <2,000 IU and confirming "immune escape" phase. He therefore needs long term nucleoside analog treatment. There is no evidence for the benefit of homeopathic treatment, and this should not distract him from the antiviral treatment which he needs to prevent severe liver damage. His smoking is a risk factor for HBV disease progression.


Pebbles is a 32 year old transsexual who is on BMT for heroin addiction. She has always smoked her heroin and never injected drugs. She was born in Asia: her blood tests show anti-HBc and HBsAg but her liver tests are always normal. She says all her family back home have Hep B. She has anti-HBe and does not have the HBeAg. She asks "I am going to get liver cancer?"

Comments: she was probably infected early in life, and is now in the "immune control" phase of HBV. She is at risk of hepatoma even if she remains in the "immune control" phase, and should be screened every six months after the age of 40, or from now if there is a family history of liver cancer. Although it is unlikely she has cirrhosis on this evidence, it is possible. If liver biopsy or fibroscan showed evidence of cirrhosis she should have hepatoma surveillance.


Dino is 38 and is on MMT. He has cleared HCV, is HIV negative and had a full course of HBV vaccination 6 years ago. After a recent test showing negative for anti-HBc, anti-HBs and HBsAg, he had two more HBV shots, but remained anti-HBs negative 6 months later. He asks “What's the point of me having all these tests & these expensive shots if they don't work?"

Comments: 5-10% of people fail to respond to vaccination, and these people should be advised that they may need passive vaccination with HBIG within 72 hours if they are exposed to HBV. HAV vaccination should be offered if he is not immune.


Betty is a 54 year old injecting drug user on MMT with regular alcohol use (40-60g/day most days). She is HCV and HIV seronegative. Her HBV serology is: anti-HBc positive, anti-HBs negative, HBsAg negative, eAg and anti-HBe also negative. Her ALT and AST are always high, with ALT>AST. Should she have HBV-DNA testing?

Comments: with isolated core antibody, it is most likely she has waned surface antibody, and a challenge with a vaccine may demonstrate this with anti-HBs becoming measurable. It is also possible she has chronic HBV and low level HBV-DNA despite not having measurable surface antigen. However, it is unlikely that such low levels of DNA would cause clinically significant disease. HBV-DNA testing is probably not needed but she should be advised to reduce her alcohol to safe levels and liver tests followed up 6-monthly.